FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Liquidia Corporation LQDA

Promising (early)   broader-coverage candidate · Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling cri

On FrontierLab's discovery record since 2026-08-05 (2 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-06), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)1936.7%
Gross margin91.8%
Gross profits / assets0.66
Rule of 401952.5
Net margin15.8%
Cash runway (months)
PEG
Price / sales27.5

Quality checklist

Fundamentals — snapshot as of 2026-08-06

StageEarly
Share issuance (YoY)18.7% · heavy issuance
Moat
TAM
P/E (trailing)640.7
EPS (trailing)$0.14
Burn multiple
Gross-margin trend (pts)33.7
Cash / assets0.55
Net debt / EBITDA-0.7
Statements as ofQ1 FY2026 · filed 2026-05-11

Momentum context — a snapshot from 2026-08-06, not current

Price at surface$89.12 (as of 2026-08-06)
52-week range$19.02 – $91.36
% off 52-wk high-2.5%
RSI (14)63
Relative volume0.7×

Risk flags

Heavy dilution (~19%/yr) — top-decile share issuers have historically underperformed.Hyper-expansion — assets up ~77% in a year; aggressive expanders have historically lagged.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-06 (end-of-day). How grades are computed →